Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
18 August 2008 - 9:30PM
PR Newswire (US)
JERUSALEM, Israel, August 18 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a
developer of oral delivery systems, announced today that its
abstract, entitled "Open Label Study to Assess the Safety,
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Five Oral
Insulin Formulations in Healthy Subjects," has been chosen for
presentation at the upcoming 44th Annual Meeting of the European
Association for the Study of Diabetes (EASD) in Rome, highlighting
the successful results from its oral insulin trials on healthy
volunteers. Oramed's poster has been assigned presentation number
PS 093 New Treatments and is available for viewing throughout the
conference. Oramed's Chief Scientific Officer, Dr. Miriam Kidron,
and Dr. Ehud Arbit, Oramed's Director of Research and Development,
will present the poster on Tuesday Sept. 9, 2008, from 12:30 p.m.
to 1:30 p.m. "The fact that Oramed has been selected to present
research at the EASD Conference underscores the importance of our
work developing an oral insulin capsule," said Nadav Kidron, Oramed
CEO. "We look forward to sharing the results of our Phase 1B trials
with top diabetes researchers from around the world." For more
information about the EASD and the upcoming conference, please
visit http://www.easd.org/. About Oramed Pharmaceuticals Oramed
Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters
are based in Jerusalem. For more information, please visit
http://www.oramed.com/ Forward-looking statements Some of the
statements contained in this press release are forward-looking
statements which involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results,
performance or achievements of the company to differ materially
from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any
forward-looking statements. Company and Investor Relation Contacts:
Oramed Pharmaceuticals Eric Rosenberg Cell: +972-54-566-7713
Office: +972-2-566-0001 Email: Media Contacts: Ruder Finn Israel
for Oramed Matthew Krieger Cell: +972-54-467-6950 Office:
+972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceuticals Inc.
CONTACT: Company and Investor Relation Contacts: Oramed
Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office:
+972-2-566-0001, Email: ; Media Contacts: Ruder Finn Israel for
Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office:
+972-2-589-2003, Email:
Copyright